Diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and haemophilus influenzae type b conjugate vaccine

PBAC's latest decision on Diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and haemophilus influenzae type b conjugate vaccine: Recommended (2022). Considered for Primary vaccination course in infants at 2, 4 and 6 months of age, and catch-up immunisation in children less than 10 years of age who have not previously received DTPa-HB-IPV-Hib vaccination.

Eligible population

Infants aged around 2, 4 and 6 months of age receiving a three-dose primary series, and children less than 10 years of age who have not previously received DTPa-HB-IPV-Hib vaccination receiving catch-up doses.

Therapy area

Vaccines

Line of therapy

First-line

Evidence base

RCT

Primary endpoint

Immunogenicity

Key trials

V419-007, V419-008, PRI03C, Studies 005, Studies 006

Comparator

Infanrix Hexa (DTPa-HB-IPV-Hib)

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis; no ICER calculated by design.

Similar precedents

• Dtpa-hepb-ipv-hib vaccine
  similarity 0.89
• Pertussis vaccine-acellular, combined with diphtheria and tetanus toxoids (dtap)
  similarity 0.74
• Diphtheria + tetanus + acellular pertussis vaccine
  similarity 0.71
• Diphtheria and tetanus toxoids combined with pertussis vaccine-acellular
  similarity 0.68
• Diphtheria, tetanus, acellular pertussis vaccine (dtpa)
  similarity 0.64
• Quadrivalent influenza vaccine
  similarity 0.63